Zacks Research Issues Positive Estimate for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at Zacks Research raised their Q3 2025 earnings estimates for shares of BioMarin Pharmaceutical in a report issued on Monday, February 17th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings of $0.73 per share for the quarter, up from their previous forecast of $0.72. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.50 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s FY2025 earnings at $2.71 EPS, Q2 2026 earnings at $0.86 EPS, Q3 2026 earnings at $0.91 EPS, Q4 2026 earnings at $0.97 EPS and FY2026 earnings at $3.52 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%.

BMRN has been the subject of several other research reports. William Blair downgraded BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 30th. Canaccord Genuity Group decreased their price target on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating for the company in a research note on Wednesday, October 30th. Robert W. Baird dropped their price objective on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. UBS Group boosted their target price on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Citigroup dropped their price target on shares of BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. Seven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock opened at $65.61 on Thursday. The business has a 50-day simple moving average of $64.79 and a 200 day simple moving average of $71.10. BioMarin Pharmaceutical has a one year low of $60.63 and a one year high of $94.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The firm has a market capitalization of $12.50 billion, a price-to-earnings ratio of 39.29, a PEG ratio of 0.57 and a beta of 0.28.

Institutional Trading of BioMarin Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $28,000. LRI Investments LLC grew its holdings in BioMarin Pharmaceutical by 856.9% during the fourth quarter. LRI Investments LLC now owns 488 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 437 shares during the period. TD Private Client Wealth LLC increased its position in BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock worth $36,000 after buying an additional 186 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at $36,000. Finally, CIBC Private Wealth Group LLC lifted its position in shares of BioMarin Pharmaceutical by 64.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 233 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.